Amylyx drug cuts low blood sugar episodes in bariatric surgery patients in key trial

Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts (AMLX)

Amylyx Pharmaceuticals, Inc. upgraded to Strong Buy after phase 3 LUCIDITY avexitide PBH results. Click for this AMLX stock update and see why I am upgrading it.

A New Use for GLP-1s? Biotech Catapults To 3-Year High.

Amylyx stock skyrocketed Tuesday after its GLP-1 drug reduced hypoglycemia in patients who've undergone bariatric surgery.

Amylyx drug cuts low blood sugar episodes in bariatric surgery patients in key trial

Aug 18 (Reuters) - Amylyx Pharmaceuticals said on Tuesday its experimental drug met its main goal in a late-stage trial for post-bariatric hypoglycemia, a ​condition marked by dangerously low blood sugar ‌levels following weight-loss surgery. In the 78...

Amylyx stock soars on GLP-1 success: here's why I'm selling

Amylyx Pharmaceuticals (AMLX) shares exploded to the upside on August 18th after the company reported blockbuster topline results from its pivotal Phase 3 LUCIDITY trial. The late-stage study evaluated avexitide – the pharmaceutical firm’s first-in-class GLP-1 receptor antagonist – in patients suffering from post-bariatric hypoglycemia (PBH). Following the meteoric surge, Amylyx stock is trading at nearly 3x its price at the start of this year. …

Amylyx Pharmaceuticals Stock Soars 48% After Avexitide Hits All Endpoints in Pivotal Phase 3 Trial

Amylyx Pharmaceuticals' shares soared 48% after announcing positive Phase 3 trial results for avexitide, a drug targeting post-bariatric hypoglycemia, marking a significant milestone for the biotech company.

Amylyx declares late-stage win with a GLP-1 antagonist in its post-ALS reset

After a turbulent few years researching ALS, Amylyx Pharmaceuticals said it has notched a success in its attempt to rebuild as a GLP-1 biotech. A Phase 3 study for avexitide, a GLP-1 receptor antagonist, hit ...